Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.94 and traded as high as $2.13. Protagenic Therapeutics shares last traded at $2.04, with a volume of 4,972 shares traded.
Protagenic Therapeutics Trading Down 4.2 %
The stock has a market cap of $8.81 million, a price-to-earnings ratio of -2.32 and a beta of 0.16. The stock has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $0.94.
Hedge Funds Weigh In On Protagenic Therapeutics
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company’s stock after acquiring an additional 41,800 shares during the quarter. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 3.47% of the stock is owned by institutional investors.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.